Sung Lee
Director of Finance/CFO bij VIR BIOTECHNOLOGY, INC.
Vermogen: 1 M $ op 31-03-2024
Profiel
Sung H.
Lee is currently the Chief Financial Officer, Secretary & Executive VP at Vir Biotechnology, Inc. He previously held positions as Vice President-Investor Relations at Gilead Sciences, Inc. from 2005 to 2019, Chief Financial Officer & Executive Vice President at Sangamo Therapeutics, Inc. from 2019 to 2021, and Chief Financial Officer at MorphoSys AG from 2021 to 2023.
Mr. Lee holds a graduate degree from the University of Southern California and an undergraduate degree from the University of California, Irvine.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
VIR BIOTECHNOLOGY, INC.
0.07% | 27-03-2024 | 100 492 ( 0.07% ) | 1 M $ | 31-03-2024 |
Actieve functies van Sung Lee
| Bedrijven | Functie | Begin |
|---|---|---|
| VIR BIOTECHNOLOGY, INC. | Director of Finance/CFO | 27-03-2023 |
Eerdere bekende functies van Sung Lee
| Bedrijven | Functie | Einde |
|---|---|---|
| MORPHOSYS AG | Director of Finance/CFO | 17-03-2023 |
| SANGAMO THERAPEUTICS, INC. | Director of Finance/CFO | 01-02-2021 |
| GILEAD SCIENCES, INC. | Investor Relations Contact | 31-10-2019 |
Opleiding van Sung Lee
| University of Southern California | Graduate Degree |
| University of California, Irvine | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 4 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| SANGAMO THERAPEUTICS, INC. | Health Technology |
| MORPHOSYS AG | Health Technology |
| VIR BIOTECHNOLOGY, INC. | Health Technology |
